According to The Insight Partners market research study of “Netherton Syndrome Market to 2027 – Global Analysis and Forecast by Therapy and Region,” the global Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2020 to 2027. The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.
Netherton syndrome is a rare disorder characterized by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. The trichorrhexis invaginata indicates short and brittle hair, atopic diathesis represents susceptibility to allergy problems while ichthyosiform erythroderma encompasses red, inflamed, scaly skin. Netherton syndrome is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, although there is no family history of the disease, the syndrome is revealed even when two healthy parents that carry the mutated recessive gene have a child, which receives both copies of the recessive gene.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00013771/
Segments:
Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment accounted for the largest share of the global market. The market growth of this segment is attributed to the increasing product launches and robust existing product pipeline. In addition, strategic activities by implemented by drug manufacturers such as collaborations, partnerships, and expansions to expedite the process of drug introduction are also projected to drive growth of the market. However, the Netherton syndrome market for the biological therapy segment is estimated to growth at the faster CAGR during the forecast period.
Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market. However, the biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. The growth of the market for the biological therapy segment is attributed to the increasing adoption of biological therapy due to its beneficial treatment outcomes.
Key Companies are:
- Lifemax Laboratories, Inc.
- Azitra, Inc.
- Sixera Pharma Ab
- Dermelix Biotherapeutics
- Matrisys Bioscience
- Quoin Pharmaceuticals Ltd.
- Krystal Biotech, Inc
Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00013771/
Below is the list of the growth strategies done by the players operating in the Netherton syndrome market:
Apr-2020: LifeMax Laboratories, Inc. has recived Food and Drug Administration (FDA) fast track designation to LM-030. The product is licensed from Novartis and currently in a Phase 2/3 pivotal clinical trial for the treatment of Netherton Syndrome. The product has previously received orphan drug designation (ODD) from both the FDA and European Commission as well as rare pediatric disease designation (RPD) from the FDA.
May-2020: Azitra, Inc., a clinical-stage medical dermatology company has received Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome (NS), a chronic genetic skin disease that can be life threatening.
Feb-2019: Exicure, Inc. and Dermelix Biotherapeutics, received a a license and development agreement to advance SNA therapeutics in rare genetic skin diseases.
Mar-2017: The Sixera Pharma, received Patent for product Benzoxazinone derivatives for treatment of skin diseases.
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00013771/
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
Contact us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-987